Global Chronic Kidney Disease (CKD) Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Chronic Kidney Disease (CKD) Drugs Market is presumed to reach the market size of nearly USD 23.69 Billion by 2032 from USD 15.06 Billion in 2023 with a CAGR of 5.16% under the study period 2024 - 2032.

Chronic kidney disease (CKD) drugs are pharmaceutical agents used to treat and manage long-term kidney damage and dysfunction. They aim to slow the progression of kidney disease, control symptoms, manage complications, and reduce the risk of cardiovascular events and mortality concerned with impaired kidney function. These drugs may include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, erythropoiesis-stimulating agents (ESAs), phosphate binders, and vitamin D analogs, among others.

MARKET DYNAMICS

The spurring incidence of risk factors such as diabetes, hypertension, obesity, and aging populations drives the prevalence of CKD, leading to a growing patient population in need of pharmacological interventions to slow disease progression, manage symptoms, and enhance quality of life. With factors such as the increasing awareness of CKD, early detection initiatives, and the implementation of screening programs driving the identification of high-risk individuals and asymptomatic cases, there is a growing demand for CKD drugs that offer renoprotective effects, cardiovascular risk reduction, and symptom relief in patients with CKD stages 1 to 5. Additionally, advancements in renal biology, pathophysiology, and biomarker research enable the identification of novel drug targets, mechanisms of action, and therapeutic strategies for CKD treatment and management.

Moreover, the increasing recognition of CKD as a global public health challenge drives market innovation as pharmaceutical companies, biotech startups, and academic researchers invest in drug discovery and development programs targeting CKD complications. Furthermore, the evolving regulatory landscape, clinical trial design, and reimbursement policies drive market competition, pricing dynamics, and market access for CKD drugs as manufacturers navigate regulatory pathways, demonstrate clinical efficacy, and secure market approvals. However, concerns over drug safety, effectiveness, and adverse effects may challenge the chronic kidney disease (CKD) drugs market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic kidney disease (ckd) drugs. The growth and trends of chronic kidney disease (ckd) drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the chronic kidney disease (ckd) drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

ACE Inhibitors
Angiotensin-Ii Receptor Blockers
Calcium Channel Blockers
Beta Blockers
Erythropoiesis-Stimulating Agents (Esas)
Diuretics
Others

By End-User

Hospitals
Specialty Clinics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Chronic Kidney Disease (CKD) Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Chronic Kidney Disease (CKD) Drugs market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Akebia Therapeutics Inc., AstraZeneca, Amgen Inc., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114354

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CHRONIC KIDNEY DISEASE (CKD) DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. ACE Inhibitors Historic and Forecast Sales By Regions
5.5. Angiotensin-II Receptor Blockers Historic and Forecast Sales By Regions
5.6. Calcium Channel Blockers Historic and Forecast Sales By Regions
5.7. Beta Blockers Historic and Forecast Sales By Regions
5.8. Erythropoiesis-stimulating Agents (ESAs) Historic and Forecast Sales By Regions
5.9. Diuretics Historic and Forecast Sales By Regions
5.10. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY END-USER

6.1. Overview By End-user
6.2. Historical and Forecast Data
6.3. Analysis By End-user
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Specialty Clinics Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CHRONIC KIDNEY DISEASE (CKD) DRUGS COMPANIES

8.1. Chronic Kidney Disease (CKD) Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CHRONIC KIDNEY DISEASE (CKD) DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Pfizer Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Sanofi
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. GSK Plc
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Kissei Pharmaceutical Co. Ltd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AbbVie Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Akebia Therapeutics Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. AstraZeneca
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Amgen Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Teva Pharmaceutical Industries Ltd.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies